Search PubMed⌕ Search

Biomedical subjects

E Briot

Publications and source records attributed to E Briot.

24 records · Page 2Linked to original sources
PubMed1990

[Malignant non-Hodgkin's lymphoma of the conjunctiva. Apropos of 14 cases treated at the Institut Gustave-Roussy].

Non-Hodgkin lymphomas (NHL) of the conjunctiva are rare. Radiotherapy is usually considered to be the choice of treatment in such situations. Reported here are 14 cases of conjunctival NHL, treated at the Institut Gustave-Roussy from 1981 to 1988. Mean age of the patients was 53 years. The series comprised 7 stages of IE, 4 stages of IIE and 3 stages of III. Histological types were mostly "low-grade" according to the Working Formulation (9 cases out of 14). The irradiation technique took advantage of a customized facial lead mask and of a direct anterior electron beam. A small cylindrical lead block, hanging some millimetres above the eye, shielded the cornea and the lens. Local control was achieved for 17 eyes treated (out of 19 irradiated), with a follow-up ranging from 5 to 90 months. The 2 relapses occurred in the same patient, and could be treated by a second line irradiation of the same type. Immediate tolerance was good. Late sequelae were rare and actually included 4 cases of cataract which clearly could not be entirely attributable to the treatment. In conclusion, this sophisticated technique appears to be efficient and non-toxic, since it was able to achieve an almost 100% local control rate, together with a very low percentage of late complications.

Adult↗
PubMed1989

Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy.

At the Institut Gustave-Roussy (IGR), from January 1982 to December 1986, 54 patients received total body irradiation (TBI) as a part of the conditioning regimen before allogeneic bone marrow transplantation. The patients were non-randomly assigned to either single dose TBI (STBI) (31 patients receiving 10 Gy at a 4.5 cGy/min dose rate, 8 Gy to the lungs) or to a hyperfractionated scheme (HTBI) (23 patients receiving 13.2 Gy in 11 fractions, 3 fractions per day, 9 Gy to the lungs). Relapse rate and overall survival were not significantly different in the two STBI and HTBI groups, in spite of a larger number of 2nd and 3rd remission patients in the HTBI subset. The incidence of interstitial pneumonitis (IP) was significantly reduced in the HTBI group (13%, versus 45% after STBI, p = 0.02). Lethality by IP was also lower after HTBI (4%, versus 26% after STBI, p = 0.08). There was no case of veno-occlusive disease of the liver in the HTBI group, whereas three cases were observed after STBI. Based on these results, the IGR activated, in January 1987, a randomized trial comparing the single dose 10 Gy TBI (8 Gy to the lung) to a new hyperfractionated schedule (11 fractions of 1.35 Gy, 3 fractions per day, 9 Gy to the lungs).

Adult↗
PubMed1977

[Application of the Moving Strip Technique of Fletcher in the radiation treatment of primary malignant tumours of the ovary (author's transl)].

The moving Strip Technique for irradiation of the abdomen perfected by Fletcher and Delclos represents considerable progress in terms of radiotherapy for carcinomas of the ovary by virtue of its simplicity, good tolerance, the homogeneous dose delivered to the entire abdominal cavity and the absence of sequelae. It is possible to deliver a dose of the order of 2.500 rads in 10 days to each abdominal segment, this being equivalent of 3,500 rads in 3,5 weeks. This moderate dose is aimed only at dealing with micronodular invasion and the superimposition of added local doses is required for residual tumour, marked using clips. Of 18 cases treated, including. 15 et stages III and IV, overall survival at 4 years is 52.5%. Two patients at stage III survived for more than 2 years with radiotherapy alone, whilst all at stages I and II are still alive. Have survived for more than two years with radiotherapy alone, whilst all at stages I and II are still alive. From a histological standpoint, the worst group seems to be adenocarcinomas (all dead). Systematic sequential surgery for excision or reduction, chemotherapy to dry out ascites, moving strip irradiation with superimposed doses locally and long term chemotherapy should make it possible to improve the prognostic results of this tumour, for which the outlook remains poor.

Adenocarcinoma↗
PubMed1976

[Dosimetry of high energy electron beams from a linear accelerator (author's transl)].

The dosimetric characteristics of the electron beams from the Sagittaire (C.G.R. MeV) linear accelerator are presented. The variations in dose output with the distance from the source are indicated for the usual treatment distances. The measurements carried out demonstrating the deviations from the inverse square law for distances. The graphs for the variation in dose output in terms of the opening of the collimator are given for square and rectangular openings. The measurements demonstrate the preponderant influence of the short side 1 of the rectangular field of the relative variation in dose output. The variations in the graphs of the deep yield in terms of beam energy, distance from the source and field dimension were studied. For the different energies, the influence of the distance from the collimator and the dimension of the field on the dose at entry and on the depth of the maximum was shown. Measurements of the deep yields were carried out in the case of rectangular fields. In each case, the side of the equivalent square field corresponding to the same deep yield as a 1 X L rectangular field was determined; a comparison was carried out with the equivalent square field defined for colbat radiation.

Electrons↗
PubMedDate not supplied

Endoluminal high-dose-rate brachytherapy with a palliative aim in esophageal cancer: preliminary results at the Institut Gustave Roussy.

Ten patients with advanced esophageal carcinoma were treated with endoluminal high-dose-rate brachytherapy at the Institut Gustave Roussy. Eight of them had recurrences after external beam radiotherapy. They were treated with a high-dose rate iridium-192 source. Five patients received 6 sessions of 4 Gy, 4 patients 3 sessions of 4 Gy, and 1 patient received 3 sessions of 8 Gy. The interval time between each session was 1 week. Seventy percent of patients improved their dysphagia, with 80% endoscopic tumor response. The Karnofsky index was improved in most of the patients. The mean survival was 4 months, and dysphagia-free survival was 2.5 months. Two patients had treatment toxicity but only a transitory WHO G1 esophagitis. Endoesophageal high-dose-rate curietherapy seems an effective technique in palliative treatments. We found low toxicity and an excellent tolerance to treatment in previously irradiated patients. The efficacy of the treatment is highly dependent on a precise tumor volume evaluation.

Aged↗